106 related articles for article (PubMed ID: 20134143)
21. Induction of graft-versus-autoimmune (GVA) disease effect against refractory psoriasis by complete donor-type chimerism and graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Kojima R; Kami M; Kim SW; Murashige N; Kishi Y; Hori A; Imataki O; Hamaki T; Sakiyama M; Masuo S; Fujisawa Y; Makimoto A; Heike Y; Tanosaki R; Takaue Y
Bone Marrow Transplant; 2003 Aug; 32(4):439-42. PubMed ID: 12900783
[TBL] [Abstract][Full Text] [Related]
22. Allogeneic stem-cell transplantation in patients with refractory acute leukemia: a long-term follow-up.
Oyekunle AA; Kröger N; Zabelina T; Ayuk F; Schieder H; Renges H; Fehse N; Waschke O; Fehse B; Kabisch H; Zander AR
Bone Marrow Transplant; 2006 Jan; 37(1):45-50. PubMed ID: 16258531
[TBL] [Abstract][Full Text] [Related]
23. The influence of early transplantation, age, GVHD prevention regimen, and other factors on outcome of allogeneic transplantation for CML following BuCy.
Copelan EA; Penza SL; Theil KS; Elder PJ; Bechtel TP; Tighe MB; Ezzone SA; Scholl MD; Belt PS; Young DC; Avalos BR
Bone Marrow Transplant; 2000 Nov; 26(10):1037-43. PubMed ID: 11108300
[TBL] [Abstract][Full Text] [Related]
24. [Fulminant hepatitis-like veno-occlusive disease of the liver after allogeneic bone marrow transplantation in acute lymphoblastic leukemia].
Naito H; Arioka H; Kobayashi R; Ishikawa Y
Rinsho Ketsueki; 1993 May; 34(5):656-61. PubMed ID: 8315837
[TBL] [Abstract][Full Text] [Related]
25. Do minitransplants have minicosts? A cost comparison between myeloablative and nonmyeloablative allogeneic stem cell transplant in patients with acute myeloid leukemia.
Cordonnier C; Maury S; Esperou H; Pautas C; Beaune J; Rodet M; Lagrange JL; Rouard H; Beaumont JL; Bassompierre F; Glückman E; Kuentz M; Durand-Zaleski I
Bone Marrow Transplant; 2005 Oct; 36(7):649-54. PubMed ID: 16044135
[TBL] [Abstract][Full Text] [Related]
26. Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment.
Blaise DP; Michel Boiron J; Faucher C; Mohty M; Bay JO; Bardoux VJ; Perreau V; Coso D; Pigneux A; Vey N
Cancer; 2005 Nov; 104(9):1931-8. PubMed ID: 16178004
[TBL] [Abstract][Full Text] [Related]
27. Reduced-intensity stem cell transplantation from an HLA-identical sibling donor in patients with myeloid malignancies.
Hamaki T; Kami M; Kim SW; Onishi Y; Kishi Y; Murashige N; Hori A; Kojima R; Sakiyama M; Imataki O; Heike Y; Tanosaki R; Masuo S; Miyakoshi S; Taniguchi S; Tobinai K; Takaue Y
Bone Marrow Transplant; 2004 May; 33(9):891-900. PubMed ID: 15048142
[TBL] [Abstract][Full Text] [Related]
28. Markers of endothelial function in pediatric stem cell transplantation for acute leukemia.
Luzzatto G; Cella G; Messina C; Randi ML; Sbarai A; Zanesco L
Med Pediatr Oncol; 2003 Jan; 40(1):9-12. PubMed ID: 12426679
[TBL] [Abstract][Full Text] [Related]
29. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
Kröger N; Zabelina T; Sonnenberg S; Krüger W; Renges H; Stute N; Finkenstein F; Mayer U; Holstein K; Fiedler W; Colberg H; Sonnen R; Kuse R; Braumann D; Metzner B; del Valle F; Erttmann R; Kabisch H; Zander AR
Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
[TBL] [Abstract][Full Text] [Related]
30. Veno-occlusive disease of the liver after allogeneic bone marrow transplantation for severe aplastic anemia.
Lee JH; Lee KH; Choi SJ; Min YJ; Kim JG; Kim S; Lee JS; Kim SH; Park CJ; Chi HS; Kim WK
Bone Marrow Transplant; 2000 Sep; 26(6):657-62. PubMed ID: 11041568
[TBL] [Abstract][Full Text] [Related]
31. Autologous stem cell transplantation in acute myeloid leukemia. Factors influencing outcome. A 13 year single institution experience.
Martins C; Lacerda JF; Lourenço F; Carmo JA; Lacerda JM
Acta Med Port; 2005; 18(5):329-37. PubMed ID: 16611537
[TBL] [Abstract][Full Text] [Related]
32. The outcome of sibling and unrelated donor allogeneic stem cell transplantation in adult patients with acute myeloid leukemia in first remission who were initially refractory to first induction chemotherapy.
Cook G; Clark RE; Crawley C; Mackinnon S; Russell N; Thomson K; Pearce RM; Towlson K; Marks DI
Biol Blood Marrow Transplant; 2006 Mar; 12(3):293-300. PubMed ID: 16503498
[TBL] [Abstract][Full Text] [Related]
33. High pre-transplant serum ferritin and busulfan-thiotepa conditioning regimen as risk factors for hepatic sinusoidal obstructive syndrome after autologous stem cell transplantation in patients with malignant lymphoma.
Hwang DY; Kim SJ; Cheong JW; Kim Y; Jang JE; Lee JY; Min YH; Yang WI; Kim JS
Leuk Lymphoma; 2016; 57(1):51-7. PubMed ID: 25899401
[TBL] [Abstract][Full Text] [Related]
34. [Hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia].
Liu QF; Sun J; Zhang Y; Liu XL; Xu D; Xu B; Feng R; Meng FY; Zhou SY
Ai Zheng; 2004 Apr; 23(4):426-9. PubMed ID: 15087032
[TBL] [Abstract][Full Text] [Related]
35. Hepatic veno-occlusive disease with severe capillary leakage after peripheral stem cell transplantation: treatment with recombinant plasminogen activator and C1-esterase inhibitor concentrate.
Heying R; Nürnberger W; Spiekerkötter U; Göbel U
Bone Marrow Transplant; 1998 May; 21(9):947-9. PubMed ID: 9613790
[TBL] [Abstract][Full Text] [Related]
36. [Severe hepatic veno-occlusive disease (VOD) which was successfully treated with supportive therapy, but subsequently developed late-recurrence].
Matsuoka S; Okamoto S; Ishida A; Wakui M; Watanabe R; Moriki T; Ikeda Y; Hirabayashi N
Rinsho Ketsueki; 1998 Feb; 39(2):139-45. PubMed ID: 9545827
[TBL] [Abstract][Full Text] [Related]
37. [Efficacy and toxicity of intravenous busulfan-based conditioning before allogeneic peripheral blood stem cell transplantation for leukemia].
Tong XZ; Xu DR; Zou WY; Li J; Luo SK; Peng AH; Zhang GC; Zheng D
Ai Zheng; 2007 Aug; 26(8):914-8. PubMed ID: 17697559
[TBL] [Abstract][Full Text] [Related]
38. Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation.
Lee JH; Choi SJ; Lee JH; Kim SE; Park CJ; Chi HS; Lee MS; Lee JS; Kim WK; Lee KH
Ann Hematol; 2005 May; 84(5):321-30. PubMed ID: 15580502
[TBL] [Abstract][Full Text] [Related]
39. Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients.
Carreras E; Rosiñol L; Terol MJ; Alegre A; de Arriba F; García-Laraña J; Bello JL; García R; León A; Martínez R; Peñarrubia MJ; Poderós C; Ribas P; Ribera JM; San Miguel J; Bladé J; Lahuerta JJ;
Biol Blood Marrow Transplant; 2007 Dec; 13(12):1448-54. PubMed ID: 18022574
[TBL] [Abstract][Full Text] [Related]
40. TIPS for veno-occlusive disease following stem cell transplantation.
Schoppmeyer K; Lange T; Wittekind C; Niederwieser D; Caca K
Z Gastroenterol; 2006 Jun; 44(6):483-6. PubMed ID: 16773513
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
